Novo Nordisk

Key Points The bulk of Novo Nordisk's sales come from weight-loss and diabetes treatments. The biotech faces competition from companies like Eli Lilly and Pfi...

Advertisement Recent share performance and business profile Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with the...

Key Points Biogen will likely benefit from increased sales of its Alzheimer's therapy, Leqembi. Both companies have been active in acquisitions. Novo Nordisk...

Eli Lilly (LLY +2.61%) has become the leader in a market marching toward the $100 billion mark. I'm talking about the weight-loss drug market, expected to reach...

Novo Nordisk (NYSE:NVO) released detailed Phase 3 OASIS 4 and STEP UP data for its oral Wegovy obesity treatment. The new results highlight sustained weight lo...

Novo Nordisk (NVO) was added as a new long idea with the potential for 52% to 117% upside. "At $46, the Street is mispricing a $50M-patient US TAM, a duopoly t...

Key Points Novo Nordisk recently posted strong quarterly results. Newer launches are boosting sales. Novo Nordisk has a strong pipeline of assets in its core...

The company said adults treated with oral semaglutide 25 mg achieved clinically meaningful weight loss regardless of whether they experienced rapid early reduct...

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its...